Russia has announced that its personalized mRNA-based cancer vaccine, Enteromix, is ready for public use and will be provided free of charge to all citizens.
The vaccine, developed by the National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology, recently completed preclinical trials with reported 100% efficacy and safety.
According to the Federal Medical and Biological Agency (FMBA), the vaccine demonstrated significant tumor reduction and slowed cancer progression in participants, with no serious side effects observed.
Enteromix is tailored to individual patients using their tumor’s genetic profile, enabling a targeted immune response against cancer cells.
Initially focused on colorectal cancer, versions for glioblastoma and melanoma are in advanced development.
FMBA head Veronika Skvortsova stated, “The vaccine is now ready for use; we are awaiting official approval.”
The announcement was made at the Eastern Economic Forum in Vladivostok, highlighting Russia’s progress in biotechnology.
The government has classified the vaccine under a specialized regulatory process due to its personalized nature and plans to cover its estimated cost of 300,000 rubles (approximately $2,869) per dose.
While the results are promising, global experts urge caution, noting the early stage of trials and small sample size of 48 volunteers.
Further validation through peer-reviewed studies and larger trials is essential to confirm long-term efficacy.
If successful, Enteromix could mark a transformative advancement in oncology, offering a safer alternative to conventional treatments like chemotherapy.
Sources: TASS, Economic Times, Times of India, NDTV
